MedPath
HSA Approval

Xorimax 250mg coated tablets

SIN13287P

Xorimax 250mg coated tablets

Xorimax 250mg coated tablets

June 1, 2007

NOVARTIS (SINGAPORE) PTE LTD

SANDOZ SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD
Licence HolderSANDOZ SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, COATED

ORAL

Medical Information

J01DC02

cefuroxime

Manufacturer Information

SANDOZ SINGAPORE PTE. LTD.

Sandoz Private Limited (Intermediate)

Pencef Pharma GmbH

Sandoz GmbH

Aurobindo Pharma Limited (Intermediate)

Active Ingredients

CEFUROXIME AXETIL 300.72 mg EQV CEFUROXIME

250 mg

Cefuroxime

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.